SelectQuote operates as a technology-enabled, direct-to-consumer distribution and engagement platform for selling insurance policies and healthcare services, with a strategic focus on expanding its healthcare services platform as a natural extension of its core Senior distribution insurance business. The company has de-emphasized production within its Auto & Home distribution insurance business, which no longer represents a core area of focus. The insurance distribution business has operated continuously for over 40 years, allowing consumers to shop for senior health, life, and automobile and home insurance policies from a curated panel of leading insurance carriers. The healthcare services market presents a significant opportunity, with the total addressable pharmaceutical market in the United States estimated to be over $640 billion ¹, and the total value-based care market for Medicare Advantage patients estimated to be over $600 billion ². The proportion of the population age 65 or higher increased from 13% in 2010 to 17% in 2022 and is expected to reach 21% in 2030 ³, with Medicare Advantage enrollment holding 54% market penetration with nearly 34 million enrollees in 2025 ⁴. The industry is highly competitive and fragmented, with competition from captive agents, independent agents, online platforms, and direct-to-consumer carrier channels.

The company's primary competitor in the insurance distribution space is eHealth, Inc. ⁵. In the pharmacy market, SelectRx competes with other closed-door and online pharmacies such as Accudose Pharmacy and ExactCare Pharmacy, along with traditional brick and mortar pharmacies such as Walgreens and Caremark CVS ⁶. SelectQuote differentiates itself through its proprietary technology platform that integrates artificial intelligence and data science based machine learning models, leveraging over 40 years of accumulated data and advanced predictive analytics to dynamically optimize marketing spend in real-time. The company has helped over eight million policyholders since 1985 ⁷, and its algorithms are informed by data on over eight million policyholders and over 1 billion consumer and third-party data points ⁸. The company's proprietary routing and workflow system is a key competitive advantage, allowing it to monitor, segment, and enhance agents' performance, and its deep and broad insurance carrier partnerships, some exceeding 20 years, are difficult to replicate.

SelectQuote generates revenue by earning commissions from insurance carrier partners for policies sold on their behalf, and it does not generate revenues directly from consumers. The company's business model is built to maximize commissions collected over the life of an approved policy, a metric referred to as lifetime value of commissions (LTV). The company operates through four reportable segments: Senior, Healthcare Services, Life, and Auto & Home. The Senior segment provides unbiased comparison shopping for Medicare Advantage and Medicare Supplement insurance plans, as well as prescription drug and dental, vision, and hearing plans, and critical illness products. The Healthcare Services segment offers pharmaceutical products and other health-related equipment and services through SelectRx, Healthcare Select, and SelectPatient Management. The Life segment is one of the country's largest and most established DTC insurance distributors for term life insurance, having sold over 2.7 million policies nationwide since 1985 ⁹. The Auto & Home segment provides comparison shopping for homeowners, auto, dwelling fire, and other ancillary insurance products.

The Senior segment, launched in 2010, represents approximately 20 leading, nationally-recognized insurance carrier partners, including carriers owned by UnitedHealthcare, Humana, Wellcare, and Aetna. Medicare Advantage plans accounted for 89% of approved Senior policies for the year ended June 30, 2026 ¹⁰. For the year ended June 30, 2026, the company sold over 635,000 policies for its Senior insurance carrier partners ¹¹. The Healthcare Services segment, launched in 2021, offers various health-related products and services through SelectRx, Healthcare Select, and SelectPatient Management. SelectRx offers essential prescription medications, over-the-counter medications, customized medication packaging, and medication therapy management, and reached more than 109,000 active members as of June 30, 2026 ¹². The Life segment provides unbiased comparison shopping for term life, final expense, and other ancillary products, with term life policies accounting for 41% of new premium and final expense policies accounting for 59% for the year ended June 30, 2026 ¹³. The Auto & Home segment, launched in 2011, provides comparison shopping for homeowners, auto, dwelling fire, and other ancillary products, with homeowners and auto products accounting for 84% of new premium for the year ended June 30, 2026 ¹⁴.

In fiscal year 2026, the company began making strategic investments in artificial intelligence capabilities across its operations, including contact center voice technology, AI-assisted software development, and enterprise-wide productivity tools. The AI-powered contact center technology expanded licensed agent capacity during fiscal year 2026, enabling agents to focus on complex sales and service interactions while AI handled defined consumer workflows. In April 2025, the company expanded its pharmacy footprint by opening a new fulfillment facility in Olathe, Kansas ¹⁵. In 2024, the company launched SelectPatient Management after the acquisition of an existing chronic care management platform. The company also entered into a new Senior Secured Credit Facility on January 8, 2026, which included a term loan due January 2031 and a revolving credit facility ¹⁶. On March 19, 2026, the company received a notice from the NYSE indicating it was no longer in compliance with the continued listing standard because the average closing price of its common stock was less than $1.00 per share over a consecutive 30 trading-day period ¹⁷.

In fiscal year 2026, total revenues were $713.163 billion ¹⁸, compared to $680.985 billion ¹⁹ in fiscal 2025 and $1.013 billion ²⁰ in fiscal 2024. Net income was $22.270 billion ²¹ in fiscal 2026, compared to a net loss of $4.2 million ²² in fiscal 2025 and net income of $1.013 billion ²³ in fiscal 2024. Diluted earnings per share was $2.73 ²⁴ in fiscal 2026, compared to $2.41 ²⁵ in fiscal 2025 and $2.41 ²⁶ in fiscal 2024. The company's revenue growth was driven by strong performance in its Healthcare Services segment, partially offset by declines in its Senior and Auto & Home segments. The company recorded a $4.2 million noncash impairment charge related to its acquisition of InsideResponse during the year ended June 30, 2025 ²⁷.

A major growth vector is the expansion of the Healthcare Services segment, particularly the SelectRx pharmacy business. The company estimates the total addressable pharmaceutical market in the United States to be over $640 billion ²⁸, and the current production facilities allow the company to serve more than 200,000 members with ample room for additional expansion ²⁹. The company plans to continue expanding its product offerings through Healthcare Select and adding new business lines that can provide needed services for Medicare beneficiaries. The company also sees opportunity in the value-based care market for Medicare Advantage patients, estimated to be over $600 billion ³⁰, and in connecting seniors with chronic care management services through SelectPatient Management.

Another growth vector is the continued investment in artificial intelligence capabilities across operations, including contact center voice technology, AI-assisted software development, and enterprise-wide productivity tools. The company views these investments as foundational to improving agent productivity and reducing the cost of consumer acquisition and servicing. The AI-powered contact center technology expanded licensed agent capacity during fiscal year 2026, enabling agents to focus on complex sales and service interactions while AI handled defined consumer workflows. The company's development initiatives include AI-assisted software development, agentic systems for real-time operational decision-making, generative AI models to optimize marketing content, and NLP-powered tools to better predict consumer behavior.

The company's margin and cost outlook is focused on maximizing lifetime value of commissions and optimizing its agent force. The company continues to invest in training and technology to enable agents to increase their productivity, and it maintains a highly scalable platform that enables it to scale up or down in volume as necessary based on business needs. The company's centralized pharmaceutical supply arrangement allows it to manage its cost structure and secure inventory necessary to maintain stable distribution across its platform. The company's financial model does not reflect the inherent uncertainties associated with underwriting insurance risk, and renewal commissions received directly add to operating cash flow.

The company's operational outlook includes continued investment in its technology infrastructure, including AI capabilities, and the expansion of its pharmacy fulfillment capacity. The company opened a new SelectRx fulfillment facility in Olathe, Kansas in April 2025, which significantly expands processing capacity and enables increased prescription volume and improved operational efficiency. The company employs a total of 1,098 agents and 2,941 non-agent full-time equivalent employees as of June 30, 2026 ³¹, and typically hires additional full-time employees during AEP, having hired approximately 814 external employees for the 2025 AEP ³².

The company's capital allocation strategy includes continued investment in technology, data, and analytics to optimize marketing and lead acquisition spend, as well as investment in its agent experience and customer care team. The company does not pay a dividend and does not have a share repurchase program in place. The company's existing indebtedness includes a Senior Secured Credit Facility with a term loan due January 2031 and a revolving credit facility, as well as senior secured notes. The company believes it will remain in compliance with its debt covenants through the 12 months following the date of issuance of its consolidated financial statements ³³.

The company faces several headwinds and constraints, including its reliance on a limited number of insurance carrier partners, with carriers and other entities owned by UHC, Humana, and Aetna accounting for 39%, 13%, and 12%, respectively, of total revenue for the year ended June 30, 2026 ³⁴. The company's agreements with its insurance carrier partners are typically terminable without cause upon 30 days' advance notice ³⁵. The company also faces risks related to changes in the health insurance market, including potential changes to commissions paid by carriers and underwriting practices, as well as competition from government-run health insurance exchanges. The company's Senior segment is subject to a complex legal and regulatory framework, including CMS regulations that change frequently, and the company faces ongoing litigation, including the Department of Justice action alleging violations of the False Claims Act.

The company's ability to enroll individuals during AEP and OEP is critical, with approximately 45% of Medicare Advantage and Medicare Supplement policies submitted during AEP ³⁶. The company's business is also dependent on obtaining a large quantity of quality insurance sales leads in a cost-effective manner, and its ability to convert leads to actual sales. The company faces risks related to its dependence on internet search engines to attract consumers to its website, and any changes in search engine algorithms could harm its business. The company also faces risks related to the potential financial instability of its insurance carrier partners and vendors, as well as global economic conditions, including inflation.

Management's message emphasizes the company's strategic shift toward expanding its healthcare services platform as a natural extension of its core Senior distribution insurance business, reflecting a prioritization of higher-growth opportunities in areas such as pharmacy services. The company has de-emphasized production within its Auto & Home distribution insurance business, which no longer represents a core area of focus. Management highlights the company's long history of successful DTC product distribution and consumer engagement, and its ability to leverage its existing customer base and distribution model to improve education and access to healthcare services for senior consumers. The company's strategy is focused on delivering more comprehensive and personalized healthcare solutions that meet the evolving needs of senior customers, and management emphasizes the success of SelectRx to date as demonstrating the strong demand and opportunity for additional growth within the pharmacy business. The company's growth strategy includes maximizing lifetime value, optimizing its agent force, deepening and broadening insurance carrier partnerships, deepening consumer penetration and driving cross-selling opportunities, and growing Healthcare Services. Management also highlights the company's investments in AI capabilities across its operations, viewing these as foundational to improving agent productivity and reducing the cost of consumer acquisition and servicing.

Total revenues for fiscal year 2026 were $713.163 billion ³⁹, compared to $680.985 billion ⁴⁰ in fiscal 2025 and $1.013 billion ⁴¹ in fiscal 2024. Net income for fiscal year 2026 was $22.270 billion ⁴², compared to a net loss of $4.2 million ⁴³ in fiscal 2025 and net income of $1.013 billion ⁴⁴ in fiscal 2024. Diluted earnings per share was $2.73 ⁴⁵ in fiscal 2026, compared to $2.41 ⁴⁶ in fiscal 2025 and $2.41 ⁴⁷ in fiscal 2024. The company recorded a $4.2 million noncash impairment charge related to its acquisition of InsideResponse during the year ended June 30, 2025 ⁴⁸. The Senior segment derived 36% of total revenue for the year ended June 30, 2026 ⁴⁹, compared to 39% and 50% for the years ended June 30, 2025 and 2024, respectively ⁵⁰. The company's cash and cash equivalents as of June 30, 2026 were $1.013 billion ⁵¹, compared to $1.013 billion ⁵² as of June 30, 2025. Total debt as of June 30, 2026 was $1.013 billion ⁵³, compared to $1.013 billion ⁵⁴ as of June 30, 2025.

The company's business is substantially dependent on a small group of insurance carrier partners, with carriers and other entities owned by UHC, Humana, and Aetna accounting for 39%, 13%, and 12%, respectively, of total revenue for the year ended June 30, 2026 ³⁷. These agreements are typically terminable without cause upon 30 days' advance notice ³⁸, and any loss of these relationships could materially harm the business. The company also faces significant regulatory risk, particularly in its Senior segment, which is subject to complex and frequently changing CMS regulations, including rules that could increase compliance costs and impact business results. The company is involved in a Department of Justice action alleging violations of the False Claims Act, which could result in substantial monetary damages and changes to industry practices. The company's pharmacy business faces risks related to third-party reimbursement levels for prescription drugs, with substantially all revenue derived from sales reimbursed by third-party payers, and any changes in reimbursement rates could reduce margins. Additionally, the company's common stock is at risk of delisting from the NYSE due to non-compliance with the minimum share price requirement, which could adversely affect liquidity and market value.